The sensitivity to change over time of the Bristol activities of daily living scale in Alzheimer's disease

Determining the minimum clinically important differences for outcomes in the DOMINO trial

“…Hence, the FDA had suggested as early as 1989 that a reversal of the natural history of cognitive decline over 6 months constituted a clinically important difference and 1.4 MMSE points corresponded to 0.5 of the mean annual rate of decline in AD (Burback et al, 1999). The functionality MCID in AD2000 was set at 3.0 BADLS points based upon a published sensitivity to change study (Byrne et al, 2000) and discussion with the researchers who had developed the BADLS. The minimum change that would constitute a clinically significant behavioural response in AD2000 was based on earlier definitions of 4.0 points (Mega et al, 1999) and 8.0 points (Kaufer et al, 1996) improvement on the NPI.…”

Montessori-Based Activities Among Persons with Late-Stage Dementia: Evaluation of Mental and Behavioral Health Outcomes

“…As we could not find reliability statistics on the BADL in prior research, Cronbach’s alpha on this measure was determined in the current study at 0.647. Previous studies have shown strong construct validity as demonstrated through a four-factor solution to match its four theoretical domains (IADLs, self-care, orientation, and mobility), convergent validity with nurse-rated ADL performance and cognitive functioning, and sensitivity to change over time (Bucks et al., 1996; Byrne, Wilson, Bucks, Hughes, & Wilcock, 2000).…”

Follow-up for Alzheimer patients: European Alzheimer disease consortium position paper

“…(78)(79)(80)(81)(82)(83) and comparison of the progression of dependence in various studies is difficult as evaluation tools are not always identical(84).Feldman et al (85) report a decline of 3.12 points per year (IC at 95%: 2.49-3.75) in 173 patients suffering from AD on the "Functional Rating Scale" which counts 40 points as the maximum. Cortes et al has shown that the progression of ADL (Activity Daily Living) loss over a period of 2 years in the REAL.FR French cohort of AD patients (mild to moderate stage mostly treated by AChEIs ), shows a worsening of 1.32 points while the mean MMSE score declines by 4.57 + 0.23 points over the same period…”